Gareth Morgan
Partner
Gareth advises life sciences clients on all exclusivity rights around pharmaceuticals and medical device products. Whether it is patents, SPCs or regulatory exclusivities, Gareth has decades of experience advising on these rights and has litigated in UK and EU courts.
Gareth's experience
-
Advising ROMA on the defence of IPEC infringement proceedings brought by Syri Limited and subsequent High Court proceedings brought claiming declarations of non-infringement.
- United Kingdom
- Technology, Science & Industry
-
Advising Sandoz AG on interim injunction proceedings, and patent revocation and infringement proceedings following the launch in the UK of its generic dapagliflozin product.
- United Kingdom
- Technology, Science & Industry
-
Advised Sandoz AG, a global generics and biosimilars manufacturer, on revocation proceedings before the UK Patents Court concerning a dosing regime patent for Rivaroxaban (Xarelto), and on the subsequent damages enquiry arising from a wrongly granted interim injunction.
- United Kingdom
- Technology, Science & Industry
-
Advised Dana Fabre, a pharmaceutical company, on its appeal against a UK IPO decision refusing a paediatric extension to its SPCs protecting Tecentriq and Bavencio.
- United Kingdom
- Professional & Public Services
-
Advising on two separate products for a global pharmaceutical company and a biotech firm, focusing on the preparation of submissions to the European Medicines Agency to secure orphan drug exclusivity at the final review stage.
- United Kingdom
- Technology, Science & Industry
-
Advising an international pharmaceutical company in due diligence on product acquisitions concerning the validity and enforceability of regulatory exclusivity rights.
- United Kingdom
- Technology, Science & Industry
-
Acting for an international clinical research organisation in developing a freedom to operate strategy in relation to patents protecting protein assay technology.
- United Kingdom
- Technology, Science & Industry
-
Represented CSL Behring, a leading biopharmaceutical company, in challenging the European Medicines Agency and the Commission's grant of a conditional marketing authorisation for a competitor gene therapy product to the CSL product marketed as Hemgenix.
- £2.6m
- United Kingdom and United States
- Technology, Science & Industry
-
Advising Sanodz in relation to proceedings seeking to revoke EP 1 893 196 and its SPC which relates to the major prostate cancer drug, enzalutamide (Xtandi).
- United Kingdom
- Technology, Science & Industry
-
Acted for Teva in cases concerning data, and market exclusivity on Tecfidera before national courts, the EU General Court and CJEU.
- United Kingdom
- Technology, Science & Industry
Credentials
-
2021Joined Pinsent Masons
-
2020Honorary Fellow of Faculty - Pharmaceutical Medicine
-
2016Qualified - Ireland
-
2001Bristol University - IP Law (Postgraduate)
-
2000Qualified - England & Wales
-
1996University of Oxford - Biochemistry (DPhil)
-
1991University of Oxford - Biochemistry (MA)
Out-Law / Insight by Gareth Morgan
People who viewed Gareth Morgan also viewed
Show me all
Bill Ryan
Partner
Bill specialises in advising the construction, engineering and energy industry sectors primarily in relation to contentious matters. His recent experience includes co-managing large teams in arbitration proceedings arising from LNG and processing plant projects in Queensland and Western Australia.
Barry McCaig
Partner, Head of Office, Glasgow
Barry is Head of the Glasgow office and of the Corporate practice group in Scotland.
Bryn Reynolds
Partner
Bryn is a chartered accountant and chartered tax advisor who advises large businesses on all indirect tax issues including VAT, IPT and customs duties. He primarily advises large financial institutions and TMT clients including FinTech.
Ben McKinley
Partner
Ben’s expertise is advising and representing employers in all aspects of employment, industrial relations, and safety law. He is highly regarded for his pragmatic and strategic advice, and works closely with clients to build trust and an in-depth understanding of their business.